论文部分内容阅读
在过去的三、四年时间里,凡是涉及原药或者出口的国内外大型展会,总能看到海利尔药业集团(下称海利尔)的特装展位,其公司高层也经常出国考察,而在国内终端市场,却很少有与之行业地位相称的巨大动作。但从今年开始,市场上出现了新的变化,海利尔动作频频。在各大省市,海利尔将召开规模较大的经销商会议,不断推出重量级新品……这似乎预示着海利尔正在进行一些变革,究其为什么变革?变革要走向何方?带着疑问,记者采访了海利尔总裁杨波涛。
In the past three to four years, all the large-scale exhibitions at home and abroad involving original drugs or exports can always see the special booths of Heilier Pharmaceutical Group (hereinafter referred to as Heilier), and the top executives of the company also often go abroad However, in the domestic terminal market, there are few huge actions commensurate with the status of the industry. However, from the beginning of this year, new changes have taken place in the market, and Heilier has frequent moves. In major provinces and cities, Heilier will hold a larger dealer meeting, continue to introduce heavyweight new ... ... This seems to indicate that Heilre is making some changes, why do they change? Where to change? With Doubt, the reporter interviewed Heier Er president Yang Bo Tao.